Key result
Ribosomal inactivation induces early responsive gene products, including proinflammatory cytokines, providing mechanistic evidence for therapeutic targets in mucosal and systemic inflammatory illness.
This review highlights noncanonical pathways of cytokine induction via ribosomal inactivation as potential therapeutic targets for mucosal and systemic inflammatory diseases.
Hypothesis-generating for ribosomal targets in inflammatory disease; prospective trials needed before clinical consideration.
Ribosomal inactivation damages 28S ribosomal RNA by interfering with its functioning during gene translation, leading to stress responses linked to a variety of inflammatory disease processes. Although the primary effect of ribosomal inactivation in cells is the functional inhibition of global protein synthesis, early responsive gene products including proinflammatory cytokines are exclusively induced by toxic stress in highly dividing tissues such as lymphoid tissue and epithelia. In the present study, ribosomal inactivation-related modulation of cytokine production was reviewed in leukocyte and epithelial pathogenesis models to characterize mechanistic evidence of ribosome-derived cytokine induction and its implications for potent therapeutic targets of mucosal and systemic inflammatory illness, particularly those triggered by organellar dysfunctions.
No takes yet. Share an insight, caveat, or question.
Yuseok Moon (2014) conducted a review in Mucosal and systemic inflammation. Ribosomal inactivation was evaluated on Cytokine induction. Ribosomal inactivation induces early responsive gene products, including proinflammatory cytokines, providing mechanistic evidence for therapeutic targets in mucosal and systemic inflammatory illness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: